Clinical Trials
2 trialsNCT05172700 2024-12-18
Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
Eli Lilly and Company
Approved for marketing
NCT00068146 2018-07-05
Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma
National Institutes of Health Clinical Center (CC)
Completed